---
figid: PMC4137125__zh40161412100003
figtitle: Schematic representation depicting deleterious effects of overnutrition
  and obesity in the vasculature and targets for DPP-4i
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4137125
filename: zh40161412100003.jpg
figlink: /pmc/articles/PMC4137125/figure/F3/
number: F3
caption: A schematic representation depicting deleterious effects of overnutrition
  and obesity in the vasculature and targets for DPP-4i. Numbered black circles 1
  through 13 indicate key components of pathology. DPP-4i improve vascular dysfunction
  through GLP-1-dependent and -independent mechanisms through modulation of insulin
  (1) and renin-angiotensin-aldosterone system (RAAS) activation (2) leading to state
  of reactive oxygen species (ROS)-induced ROS and mitochondrial ROS amplification
  (3) and endoplasmic reticular (ER) stress (4). Advanced glycation end products (AGE)
  (5), hyperglycemia (6), and low-grade endotoxemia (7) collectively contribute to
  intracellular oxidative stress. The exacerbated state of oxidative stress induces
  activation of redox sensitive kinases that influence the phosphorylation state of
  insulin receptor substrate-1 (IRS-1) to reduce nitric oxide (NO) generation via
  the phosphoinositide 3-kinase (PI3K)/Akt/endothelial NO synthase (eNOS) signaling
  pathway while favoring signaling through the Shc Ras/MEK/MAPK to increase synthesis
  of endothelin-1 (ET-1). GLP-1 mediated activation of eNOS (8) and cAMP responsive
  element binding protein (CREB) (9) also contribute to vascular protection by DPP-4i.
  Dyslipidemia (10) and dysfunctional immunity (11) and dysfunctional visceral and
  perivascular adipose tissue (12) further contribute to vascular injury and inflammation.
  Thus the interaction of vascular cells, immune cells and adipose tissue causes abnormalities
  in vascular function and remodeling (13). DPP-4i (indicated by yellow boxes) modulate
  different components of pathways that could act to improve vascular function. RAGE,
  receptor for AGE; TLR, Toll-like receptor; Treg, regulatory T cells; Th, T-helper
  cells; WBC, white blood cell; MCP-1, monocyte chemoattractant protein-1; Ox-LDL,
  oxidized LDL; NOX, NADPH oxidase; AT1R, angiotensin type 1 receptor; MR, mineralocorticoid
  receptor; EC, endothelial cell; Ets-1, E26 transformation-specific-1; Ser P, serine
  phosphorylation; Tyr P, tyrosine phosphorylation; PDK1, 3-phosphoinositide-dependent
  protein kinase-1; AMPK, AMP-activated protein kinase; AC, adenylate cyclase; HO-1,
  hemoxygenase-1; NQQ1, quinine reductase.
papertitle: Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular
  system.
reftext: Annayya R. Aroor, et al. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H477-H492.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.931707
figid_alias: PMC4137125__F3
figtype: Figure
redirect_from: /figures/PMC4137125__F3
ndex: 4f71dab5-df0a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4137125__zh40161412100003.html
  '@type': Dataset
  description: A schematic representation depicting deleterious effects of overnutrition
    and obesity in the vasculature and targets for DPP-4i. Numbered black circles
    1 through 13 indicate key components of pathology. DPP-4i improve vascular dysfunction
    through GLP-1-dependent and -independent mechanisms through modulation of insulin
    (1) and renin-angiotensin-aldosterone system (RAAS) activation (2) leading to
    state of reactive oxygen species (ROS)-induced ROS and mitochondrial ROS amplification
    (3) and endoplasmic reticular (ER) stress (4). Advanced glycation end products
    (AGE) (5), hyperglycemia (6), and low-grade endotoxemia (7) collectively contribute
    to intracellular oxidative stress. The exacerbated state of oxidative stress induces
    activation of redox sensitive kinases that influence the phosphorylation state
    of insulin receptor substrate-1 (IRS-1) to reduce nitric oxide (NO) generation
    via the phosphoinositide 3-kinase (PI3K)/Akt/endothelial NO synthase (eNOS) signaling
    pathway while favoring signaling through the Shc Ras/MEK/MAPK to increase synthesis
    of endothelin-1 (ET-1). GLP-1 mediated activation of eNOS (8) and cAMP responsive
    element binding protein (CREB) (9) also contribute to vascular protection by DPP-4i.
    Dyslipidemia (10) and dysfunctional immunity (11) and dysfunctional visceral and
    perivascular adipose tissue (12) further contribute to vascular injury and inflammation.
    Thus the interaction of vascular cells, immune cells and adipose tissue causes
    abnormalities in vascular function and remodeling (13). DPP-4i (indicated by yellow
    boxes) modulate different components of pathways that could act to improve vascular
    function. RAGE, receptor for AGE; TLR, Toll-like receptor; Treg, regulatory T
    cells; Th, T-helper cells; WBC, white blood cell; MCP-1, monocyte chemoattractant
    protein-1; Ox-LDL, oxidized LDL; NOX, NADPH oxidase; AT1R, angiotensin type 1
    receptor; MR, mineralocorticoid receptor; EC, endothelial cell; Ets-1, E26 transformation-specific-1;
    Ser P, serine phosphorylation; Tyr P, tyrosine phosphorylation; PDK1, 3-phosphoinositide-dependent
    protein kinase-1; AMPK, AMP-activated protein kinase; AC, adenylate cyclase; HO-1,
    hemoxygenase-1; NQQ1, quinine reductase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pp4-19C
  - Tm1
  - Tm2
  - Low
  - serp
  - Shc
  - 18w
  - tok
  - tlr-2
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Pdk1
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Akt
  - MKP-4
  - p38b
  - rl
  - Dsor1
  - Mtk
  - cad
  - .na.character
  - Drep4
  - Ca-alpha1D
  - shg
  - Nox
  - ar
  - CrebB
  - CrebA
  - Dif
  - dl
  - Rel
  - SNF4Agamma
  - AMPKalpha
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - mr
  - ec
  - Mmp2
  - Ho
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - GlyP
  - TH
  - DPP4
  - CCL2
  - IL6
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - IRS1
  - TYRP1
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDK1
  - PDPK1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AGER
  - MOK
  - AKT1
  - AKT2
  - AKT3
  - NOS3
  - ENO4
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CAD
  - DFFB
  - ACOD1
  - DECR1
  - EDN1
  - AR
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - NFKB1
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - ETS1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - MMP2
  - TGFB1
  - ICAM1
  - HMOX1
  - GLP1R
  - GCG
  - EHMT1
  - ZGLP1
  - IGLP1
  - ANGPT2
  - VPS51
  - ser
  - superoxide
  - Tyr
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
